- Author:
Chun-chao MA
1
;
Xiao-dong ZHU
Author Information
- Publication Type:Journal Article
- Keywords: Parkinson's disease; Parkinson′s disease with mild cognitive impairment(PD-MCI); Parkinson′s disease with dementia (PDD); biomarkers; cholinesterase inhibitors
- From: Chinese Journal of Practical Internal Medicine 2019;39(09):769-774
- CountryChina
- Language:Chinese
- Abstract: Parkinson's disease(PD) is a progressive neurodegenerative disease characterized by motor symptoms such as rigidity, rest tremor, and bradykinesia. However, evidence demonstrated that PD encompasses several non-motor disturbances as well, such as cognitive impairment. Mild cognitive impairment can be present since early stages of the disease, and characterized by impairments in several cognitive domains including executive functions, attention, and visuospatial skills, language, and memory; In advanced stages of the disease, cognitive defects can develop into dementia and there is a considerable heterogeneity in the cognitive impairments. In this review, we focus on the clinical characteristics, biomarkers, and drug and non-drug treatments of cognitive impairment in Parkinson's disease, hoping to provide help for clinical practice.